Excited to share biomarker analysis of CM649 Nature Medicine Yelena Y. Janjigian MD Nivo benefit was enriched in TMB-H> EBV and GS > CIN. Targeted tx is needed for CIN. Nivo+Ipi benefit was seen in Treg↑ (FOXP3+CCR8), supporting Treg or CCR8 targeting tx in GC. nature.com/articles/s4159…

Always a pleasure to chair a meeting with Yelena Y. Janjigian MD! Please join us for our 1st combined solid tumor hybrid meeting: Great Debates in Solid Tumors. Great Debates Register: hmpglobalevents.com/gdst/agenda 🤩Namrata (Neena) Vijayvergia MD #NET at 10AM today. #Cancer #cancerresearch

Look at this!! 👀 New trends in cancer cases show a major change in #StomachCancer in women especially. We need more research to understand the causes for this. #CancerResearch National Cancer Institute NoStomachForCancer Debbie's Dream Foundation: Curing Stomach Cancer UMGCCC

Running the CUIMC Team Relay Marathon for team Cure Stomach Cancer with Moy and Ryeom lab members

Moy lab at AACR

Our analysis of Claudin18.2 expression in gastroesophageal adenocarcinoma in a diverse patient cohort with higher positivity in Hispanic patients. Presented by Dr. Sara Wallam who is applying for heme/onc fellowship this cycle!

Sungjoo Jang presenting our work on PKMYT1 inhibition in CCNE1-amplified gastric cancer. Thankful for grant funding from AACR and Debbie’s Dream Foundation to support this work! Debbie's Dream Foundation: Curing Stomach Cancer

Super⭐️ oncology fellow Lawrence Wu presenting work on TEAD inhibition in diffuse gastric cancer #AACR

nbcnews.com/health/cancer/…

Dr. Lawrence Wu presenting our work on clinicogenomic profiling of signet ring carcinoma across organ sites. Awarded both an ASCO Conquer Cancer Foundation Merit Award and CAHON Young Investigator Award! #ASCO25

Excited to share our study led by fellow Lawrence Wu, focusing on the molecular characterization of early-onset esophagogastric cancer. We explore transcriptional profiles, immune microenvironment, and real-world survival outcomes. rdcu.be/ewEsO

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... sciencedirect.com/science/articl… Led by very talented Joseph J Zhao and Kennedy Ng. Raghav Sundar

Multi-omic characterization of EOEGC (<50 years) 🔗 nature.com/articles/s4169… 📊 5,175 pts (EOEGC N= 530) 👩‍⚕️ More in female, Black, Asian, Hispanic/Latino 🧬 ↑ CDH1 mut; CNAs: FGFR2, CCNE1, MYC; ARHGAP26 fusion 🛡️ ↓ MSI-H, TMB-H, PD-L1+ 🦠 ↑ M2, ↓ M1 📈 EMT & coag ↑

Diffuse gastric cancer (DGC) lacks validated targets & carries poor outcomes. Ryan Moy Herbert Irving Comprehensive Cancer Center presents data on FAK inhibition + MAPK blockade as a new strategy. Avutometinib(RAF/MEK clamp) + defactinib (FAK inhibitor) show synergy in DGC models. #DAVAGI

CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, Ryan Moy Herbert Irving Comprehensive Cancer Center discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.

Pictures from my Velocity Ride on this beautiful fall day - grateful for the ability to contribute and raise $ for our patients and for cancer research Herbert Irving Comprehensive Cancer Center - velocityride.org/teams/5600/don…

5 miles for my 5th Velocity Ride Raising funds for our patients and cancer research: velocityride.org/participants/6…

We have seen the mountain ⛰️ top! MATTERHORN OS #ESMO25 OS continues to ⬆️over time (~7% 3y) Benefit independent of PD-L1 Enough now to adopt as SOC? #ESMOAmbassadors

Read how Columbia’s newly appointed Director of Hepatobiliary Cancers and Director of Liver Transplant Oncology Aiwu Ruth He, MD, PhD, is bridging the lab and the clinic to transform liver cancer care at Columbia Medicine / Columbia Surgery cancer.columbia.edu/news/aiwu-ruth…

Congratulations to the Matterhorn study team. FDA approval independent of PD-L1 status. fda.gov/drugs/resource…